Efficacy, Safety, and Lot-to-Lot Immunogenicity of an Inactivated SARS-CoV-2 Vaccine
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial
Lancet 2021 Nov 11;[EPub Ahead of Print], R Ella, S Reddy, W Blackwelder, V Potdar, P Yadav, V Sarangi, VK Aileni, S Kanungo, S Rai, P Reddy, S Verma, C Singh, S Redkar, S Mohapatra, A Pandey, P Ranganadin, R Gumashta, M Multani, S Mohammad, P Bhatt, L Kumari, G Sapkal, N Gupta, P Abraham, S Panda, S Prasad, B Bhargava, K Ella, KM VadrevuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.